FrancophonIA/ELRC3.0 huggingface dataset:
English: Intrathecal treatment of lymphomatous meningitis.
Croatian: Za intratekalno liječenje limfomatoznog meningitisa.
English: Radiolabels for cytarabine and DOPC were distributed rapidly throughout the neuraxis.
Croatian: Radioaktivno obilježeni citarabin i DOPC brzo su se distribuirali čitavom neuralnom osovinom.
English: Severe neurological side effects have been reported with the use of DepoCyte.
Croatian: Prijavljene su ozbiljne neurološke nuspojave povezane s primjenom DepoCytea.
English: An overdose with DepoCyte may be associated with severe arachnoiditis including encephalopathy.
Croatian: Predoziranje DepoCyteom može biti udruženo s pojavom teškog arahnoiditisa, uključujući encefalopatiju.
English: Vigorous shaking should be avoided.
Croatian: Treba izbjegavati žustro mućkanje.
English: Each pack contains a single vial.
Croatian: Pakovanje sadrži jednu bočicu.
English: Administration of DepoCyte in combination with other neurotoxic chemotherapeutic agents or with cranial/spinal irradiation may increase the risk of neurotoxicity.
Croatian: Primjena DepoCytea u kombinaciji s drugim neurotoksičnim kemoterapeuticima ili zračenjem glave/kralježnice može povećati rizik nastanka neurotoksičnosti.
English: No studies assessing the impact of cytarabine on fertility are available in the literature.
Croatian: Ispitivanja o utjecaju citarabina na plodnost u literaturi nisu dostupna.
English: Fertility studies to assess the reproductive toxicity of DepoCyte have not been conducted.
Croatian: Ispitivanja plodnosti u smislu procjene reproduktivne toksičnosti DepoCytea nisu provedena.
English: DepoCyte should be withdrawn from the vial immediately before administration; the medicinal product should be used within 4 hours of withdrawal from the vial.
Croatian: DepoCyte treba navući iz bočice neposredno prije primjene; lijek treba upotrijebiti unutar 4 sata od navlačenja iz bočice.
English: Male patients undergoing DepoCyte treatment should use a reliable contraceptive method.
Croatian: Muškarci koji se liječe DepoCyteom trebaju koristiti učinkovitu metodu kontracepcije.
English: Arachnoiditis, a very common adverse reaction associated with DepoCyte, is a syndrome manifested by several adverse reactions.
Croatian: Arahnoiditis, česta nuspojava povezana s DepoCyteom, jest sindrom koji se očituje s nekoliko nuspojava.
English: Infectious meningitis may be associated with intrathecal administration.
Croatian: Nastanak infektivnog meningitisa može biti povezan s intratekalnom primjenom.
English: Unused medicinal product must not be used subsequently.
Croatian: Neiskorišteni lijek ne smije se više koristiti.
English: DepoCyte is used in adults to kill lymphoma tumour cells.
Croatian: DepoCyte se koristi u odraslih osoba za uništavanje tumorskih stanica limfoma.
English: In contrast, intrathecal administration of 30 mg free cytarabine has shown a biphasic CSF concentration profile with a terminal phase half-life of about 3.4 hours.
Croatian: Nasuprot ovome, intratekalna primjena 30 mg slobodnog citarabina pokazuje bifazičnu krivulju koncentracije u cerebrospinalnoj tekućini s poluvijekom u terminalnoj fazi od oko 3,4 sata.
English: Vials should be allowed to warm to room temperature (18°C -22°C) for a minimum of 30 minutes and be gently inverted to resuspend the particles immediately prior to withdrawal from the vial.
Croatian: Bočice je potrebno ostaviti da se zagriju na sobnoj temperaturi (18 - 22 °C) najmanje 30 minuta i nježno preokrenuti bočicu neposredno prije navlačenja lijeka kako bi se čestice suspenzije raspršile.
English: All patients receiving DepoCyte should be treated concurrently with dexamethasone to mitigate the symptoms of arachnoiditis.
Croatian: Svi bolesnici koji primaju DepoCyte trebali bi istovremeno primati deksametazon radi ublažavanja simptoma arahnoiditisa.
English: Kolarova 7, 10000 Zagreb Tel.: +385 1 2303 446
Croatian: Medis Adria d.o.o. Kolarova 7, 10000 Zagreb Tel.: +385 1 2303 446
English: The results of acute and subacute toxicity studies performed in monkeys suggested that intrathecal DepoCyte was tolerated up to a dose of 10 mg (comparable to a human dose of 100 mg).
Croatian: Rezultati ispitivanja akutne i subakutne toksičnosti provedenih na majmunima ukazuju da se DepoCyte dobro podnosi u dozama do 10 mg (usporedivo s dozom od 100 mg u ljudi).
English: What DepoCyte is and what it is given for What you need to know before you are given DepoCyte
Croatian: Što je DepoCyte i za što se primijenjuje Što morate znati prije nego što počnete primati DepoCyte Kako se primjenjuje DepoCyte Moguće nuspojave
English: Very common: pyrexia Common: pyrexia Very common: pyrexia *Cycle length was 2 weeks during which the patient received either 1 dose of DepoCyte or 4 doses of cytarabine or methotrexate.
Croatian: Vrlo često: pireksija Često: pireksija Vrlo često: pireksija *Dužina ciklusa iznosila je 2 tjedna , za vrijeme kojih je pacijent primio 1 dozu DepoCytea ili 4 doze citarabina ili metotreksata.
English: During the 1 month Induction phase of treatment, DepoCyte was administered intrathecally as 50 mg every 2 weeks, and unencapsulated cytarabine as 50 mg twice a week.
Croatian: Tijekom mjesec dana indukcijske terapije, DepoCyte je primijenjen intratekalno u dozi od 50 mg svaka 2 tjedna, a neinkapsulirani citarabin u dozi od 50 mg dva puta tjedno.
English: Because of possible excretion in human milk and because of the potential for serious adverse reactions in nursing infants, the use of DepoCyte is not recommended in breast-feeding women.
Croatian: Zbog mogućeg izlučivanja lijeka u majčinio mlijeko i zbog njegovih potencijalno ozbiljnih nuspojava u dojenčadi, ne preporučuje se primjena DepoCytea tjekom dojenja.
English: Women should not breast-feed during treatment as DepoCyte may enter breast milk.
Croatian: Dojilje ne bi trebale dojiti za vrijeme liječenja jer se DepoCyte izlučuje u majčino mlijeko.
English: DepoCyte is a sterile white to off-white-suspension.
Croatian: DepoCyte je sterilna bijela do gotovo bijela suspenzija.
English: Therefore, as with any intrathecal cytotoxic therapy, consideration should be given to the need for assessment of CSF flow before treatment is started.
Croatian: Zbog toga, kao i kod bilo koje intratekalne citotoksične terapije, prije početka liječenja neophodna je procjena protoka cerebrospinalne tekućine.
English: In an open-label non-comparative dose escalation study in 18 paediatric patients (4 to 19 years) with leukaemic meningitis or neoplastic meningitis due to primary brain tumour, an intrathecal dose of 35 mg was identified as the maximum tolerated dose.
Croatian: U otvorenom, nekomparativnom ispitivanju s povećanjem doza u 18 pedijatrijskih bolesnika (od 4 do 19 godina starosti) s leukemijskim ili neoplastičnim meningitisom nastalim zbog primarnog moždanog tumora, utvrđena je maksimalna podnošljiva intratekalna doza od 35 mg.
English: DepoCyte patients received a median of 5 cycles (doses) per patient (range 1 to 10 doses) with a median time on therapy of 90 days (range 1 to 207 days).
Croatian: Medijan broja ciklusa koji su primili bolesnici liječeni DepoCyteom je bio 5 ciklusa (doza) po bolesniku (raspon od 1 do 10 doza) sa medijanom dužine trajanja terapije od 90 dana (raspon od 1 do 207 dana).
English: If it persists, treatment with DepoCyte should be discontinued.
Croatian: Ako znakovi perzistiraju, liječenje DepoCyteom treba prekinuti.
English: Median progression-free survival (defined as time to neurological progression or death) for all treated patients was 77 versus 48 days for DepoCyte versus unencapsulated cytarabine, respectively.
Croatian: Medijan preživljenja bez progresije bolesti (definiran kao vrijeme do neurološke progresije ili smrti) iznosio je za sve liječene bolesnike 77 naspram 49 dana u korist DepoCytea u odnosu na neinkapsulirani citarabin.
English: The dose for adults is 50 mg (one vial of DepoCyte).
Croatian: Doza za odrasle iznosi 50 mg (jedna bočica DepoCytea).
English: Unused medicinal product must be discarded and not used subsequently.
Croatian: Neiskorišteni lijek mora se baciti i više ne koristiti.
English: Anaphylactic reactions following intravenous administration of free cytarabine have been rarely reported.
Croatian: Anafilaktičke reakcije nakon intravenskog davanja slobodnog citarabina, opisane su rijetko.
English: These reactions have been reported mainly from post-marketing experience with DepoCyte as spontaneous case reports.
Croatian: Ove su nuspojave zabilježene temeljem iskustva s DepoCyteom nakon puštanja lijeka na tržište i uglavnom kao spontani prikazi slučajeva.
English: Each vial contains 5 ml of suspension for a single injection.
Croatian: Jedna bočica sadrži 5 ml suspenzije za jednokratnu injekciju.
English: In-line filters must not be used when administering DepoCyte.
Croatian: Prilikom primjene DepoCytea ne smiju se koristiti In-line filtri.
English: A qualified and experienced doctor or physician in the treatment of cancer will inject DepoCyte in the spinal fluid or lumber sac.
Croatian: Iskusan i kvalificirani liječnik za liječenje zloćudnih bolesti injicirat će DepoCyte u cerebrospinalnu tekućinu ili lumbalnu vreću.
English: The majority of DepoCyte patients went on beyond Induction to receive additional therapy.
Croatian: Većina bolesnika koji su primali DepoCyte nastavilo je, nakon razdoblja indukcijske terapije, s dodatnim liječenjem.
English: DepoCyte must not be mixed with any other medicinal products.
Croatian: DepoCyte se ne smije miješati s niti jednim drugim lijekom.
English: Cytarabine caused the transformation of hamster embryo cells and rat H43 cells in vitro.
Croatian: Citarabin je uzrokovao transformaciju embrionalnih stanica hrčka i stanica štakora H43 u in vitro testovima.
English: For the treatment of lymphomatous meningitis, the dose for adults is 50 mg (one vial) administered intrathecally (lumbar puncture or intraventricularly via an Ommaya reservoir).
Croatian: Za liječenje limfomatoznog meningitisa, doza za odrasle iznosi 50 mg (jedna bočica) primijenjena intratekalno (lumbalnom punkcijom ili intraventrikularno pomoću Ommaya rezervoara).
English: See ‘Precautions for the handling and disposal of DepoCyte' below.
Croatian: Vidjeti „Mjere za rukovanje i zbrinjavanje DepoCytea“ u nastavku.
English: България ТП Мундифарма Медикъл ООД
Croatian: ТП Мундифарма Медикъл ООД Тел.
English: Do not use this medicine if you notice severe discolouration, a changed appearance or a defective container.
Croatian: DepoCyte se ne smije upotrijebiti ako primijetite izrazitu promjenu boje, promjenu izgleda ili oštećenje spremnika.
English: Following administration by lumbar puncture, it is recommended that the patient should be instructed to lie flat for one hour.
Croatian: Nakon aplikacije lumbalnom punkcijom, preporučuje se savjetovati bolesniku da leži na ravnom sat vremena.
English: Lymphomatous meningitis is a condition in which tumour cells have invaded the fluid or membranes that surround the brain and spinal cord.
Croatian: Limfomatozni meningitis je stanje u kojem su tumorske stanice prodrle u tekućinu ili membrane koje obavijaju mozak i leđnu moždinu.
English: How to store DepoCyte
Croatian: Kako čuvati DepoCyte
English: Type I glass vial closed with a fluororesin faced butyl rubber stopper and sealed with an aluminium flip-off seal containing 50 mg cytarabine in 5 ml suspension.
Croatian: Staklena bočica (staklo tip I), začepljena čepom od butil gume i fluorirane smole i aluminijskim flip- off zaštitnim poklopcem, koja sadrži 50 mg citarabina u 5 ml suspenzije.
English: Pharmacokinetic parameters of DepoCyte (75 mg) in neoplastic meningitis patients in whom the medicinal product was administered either intraventricularly or by lumbar puncture suggest that exposure to the active substance in the ventricular or lumbar spaces is similar regardless of the route of administration.
Croatian: Farmakokinetički parametri za DepoCyte (75 mg) u bolesnika s neoplastičnim meningitisom kod kojih je lijek primijenjen bilo intraventrikularno bilo putem lumbalne punkcije, upućuju da je izloženost djelatnoj tvari u ventrikularnom ili lumbalnom prostoru jednaka, bez obzira na put primjene.
English: No further reconstitution or dilution is required.
Croatian: Nema potrebe za dodatnom pripremom za primjenu ili razrjeđivanjem.
English: DepoCyte should be withdrawn from the vial immediately before administration.
Croatian: DepoCyte treba navući iz bočice neposredno prije primjene.
English: Cytarabine, when administered intrathecally, has been associated with nausea, vomiting and serious central nervous system toxicity which can lead to a permanent deficit, this includes blindness, myelopathy and other neurological toxicity.
Croatian: Intratekalna primjena citarabina povezana je s pojavom mučnine, povraćanja i znakovima ozbiljne toksičnosti središnjeg živčanog sustava koja može dovesti do trajnih oštećenja, što uključuje sljepoću, mijelopatiju i druga toksična neurološka oštećenja.
English: For cell-cycle phase specific antimetabolites the duration of exposure of neoplastic cells to cytotoxic concentrations is an important determination of efficacy.
Croatian: Za antimetabolite specifične za određenu fazu staničnog ciklusa, dužina ekspozicije neoplastičnih stanica njihovom citotoksičnom utjecaju, važna je za utvrđivanje njihove djelotvornosti.
English: No definite interactions between DepoCyte delivered intrathecally and other medicinal products have been established.
Croatian: Nisu utvrđene definitivne interakcije između intratekalno primijenjenog DepoCytea i drugih lijekova.
English: The distribution and clearance of cytarabine and of the predominant phospholipid component of the lipid particle (DOPC) following intrathecal administration of DepoCyte was evaluated in rodents.
Croatian: Distribucija i klirens citarabina i predominirajućih fosfolipidnih komponenti lipidnih čestica (DOPC) nakon intratekalne primjene DepoCytea ispitani su na glodavcima.
English: Blood and lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava DepoCyte
English: Table 2: Adverse reactions possibly reflecting neurotoxicities in Phase II, III, and IV patients receiving DepoCyte 50 mg (n = 99 cycles) or cytarabine ( n = 84 cycles)
Croatian: Tablica 2: Nuspojave koje moguće ukazuju na neurotoksičnost u fazi II, III i IV u bolesnika koji primaju DepoCyte 50 mg (n = 99 ciklusa) ili citarabin ( n = 84 ciklusa)
English: What you need to know before you are given DepoCyte DepoCyte should not be given
Croatian: Što morate znati prije nego što počnete primati DepoCyte
English: If patients develop neurotoxicity, subsequent doses of DepoCyte should be reduced, and treatment should be discontinued if toxicity persists.
Croatian: Dođe li u bolesnika do razvoja neurotoksičnosti, sljedeću bi dozu DepoCytea trebalo smanjiti, a ako znaci toksičnosti perzistiraju liječenje treba prekinuti.
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Croatian: Unutar svake grupe nuspojave su navedene prema ozbiljnosti, od ozbiljnijih prema manje ozbiljnima.
English: Because the systemic exposure to free cytarabine following intrathecal treatment with DepoCyte is negligible, the risk of impaired fertility is likely to be low (see section 5.3).
Croatian: Budući da je sistemska izloženost slobodnom citarabinu nakon intratekalne primjene DepoCytea zanemariva, rizik njegovog štetnog utjecaja na plodnost vjerojatno je nizak (vidjeti dio 5.3).
English: In an open-label, active-controlled, multicentre clinical study, 35 patients with lymphomatous meningitis (with malignant cells found on CSF cytology) were randomised to intrathecal therapy with either DepoCyte (n=18) or unencapsulated cytarabine (n=17).
Croatian: U otvorenom, aktivno kontroliranom, multicentričnom kliničkom ispitivanju, 35 bolesnika s limfomatoznim meningitisom (s malignim stanicama u ciotološkom nalazu cerebrospinalne tekućine) metodom slučajnog odabira primilo je intratekalno DepoCyte (n=18) ili neinkapsulirani citarabin (n=17).
English: Very common: arachnoiditis, confusion, headache Very common: arachnoiditis, headache Common: confusion
Croatian: Vrlo često: arahnoiditis, konfuzija, glavobolja Vrlo često: arahnoiditis, glavobolja Često: konfuzija
English: Encapsulated cytarabine concentrations and the counts of the lipid particles in which the cytarabine is encapsulated in followed a similar distribution pattern.
Croatian: Koncentracije inkapsuliranog citarabina i broj lipidnih čestica u kojima je citarabin inkapsuliran slijede isti obrazac distribucije.
English: The transfer rate of cytarabine from CSF to plasma is slow and the conversion to uracil arabinoside (ara-U), the inactive metabolite, in the plasma is fast.
Croatian: Stopa prelaska citarabina iz cerebrospinalne tekućine u plazmu je spora, a konverzija citarabina u plazmi u inaktivni metabolit uracil arabinozid (ara-U) je brza.
English: DepoCyte (n = 929 cycles)
Croatian: DepoCyte (n = 929 ciklusa)
English: DepoCyte is to be administered by slow injection over a period of 1-5 minutes directly into the cerebrospinal fluid (CSF) via either an intraventricular reservoir or by direct injection into the lumbar sac.
Croatian: DepoCyte treba primjenjivati sporom injekcijom, kroz razdoblje od 1-5 minuta, izravno u cerebrospinalnu tekućinu (CSF) bilo pomoću intraventrikularnog rezervoara ili izravnim injiciranjem u lumbalnu vreću.
English: It is not known whether cytarabine is excreted in human milk following intrathecal administration.
Croatian: Nije poznato izlučuje li se citarabin u majčino mlijeko nakon intratekalne primjene.
English: Patients receiving DepoCyte should be concurrently treated with corticosteroids (e.g. dexamethasone) to mitigate the symptoms of arachnoiditis (see section 4.8), which is a very common adverse reaction.
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi Bolesnike koji primaju DepoCyte treba istovremeno liječiti kortikosteroidima (npr. deksametazonom) radi ublažavanja simptoma arahnoiditisa (vidjeti dio 4.8), koji je česta nuspojava.
English: One ml of suspension contains 10 mg cytarabine.
Croatian: Jedan ml suspenzije sadrži 10 mg citarabina.
English: Very common: weakness, pyrexia Common: fatigue Very common: weakness, pyrexia, fatigue *Induction and Maintenance cycle lengths were 2 and 4 weeks, respectively, during which the patient received either 1 dose of DepoCyte or 4 doses of cytarabine.
Croatian: Vrlo često: opća slabost, pireksija Često: umor Vrlo često: opća slabost, pireksija *Dužina ciklusa indukcijske terapije i terapije održavanja iznosila je 2 i 4 tjedna, tijekom kojih je bolesnik primio ili 1 dozu DepoCytea ili 4 doze citarabina.
English: No carcinogenicity, mutagenicity or impairment of fertility studies have been conducted with DepoCyte.
Croatian: Studije kancerogenosti, mutagenosti i utjecaja DepoCytea na oštećenje plodnosti nisu provedena.
English: Although significant systemic exposure to free cytarabine is not expected following intrathecal treatment, some effects on bone marrow function cannot be excluded.
Croatian: Iako se nakon intratekalne primjene ne očekuje značajna sustavna izloženost slobodnom citarabinu, ne mogu se isključiti neki njegovi učinci na koštanu srž.
English: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Croatian: Lijek se izdaje na ograničeni recept (Vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
English: DepoCyte is a white to off-white-suspension for injection supplied in a glass vial.
Croatian: DepoCyte je bijela do gotovo bijela suspenzija za injekciju dostupna u staklenim bočicama.
English: Cytarabine patients not completing all 4 doses within a cycle are counted as a complete cycle.
Croatian: Bolesnici koji nisu dobili sve 4 doze citarabina unutar ciklusa, su brojeni kao da su dobili kompletan ciklus citarabina.
English: No overdoses with DepoCyte have been reported.
Croatian: Nema izvješća o predoziranju s DepoCyteom.
English: The frequency of possible side effects listed below is defined using the following convention: very common (affects more than 1 user in 10); common (affects 1 to 10 users in 100); uncommon (affects 1 to 10 users in 1,000); rare (affects 1 to 10 users in 10,000); very rare (affects less than 1 user in 10,000); not known (frequency cannot be estimated from the available data).
Croatian: Učestalost mogućih nuspojava navedena je u nstavku prema sljedećoj konvenciji: vrlo često (javljaju se kod 1 od 10 korisnika); često (javljaju se kod 1 do 10 korisnika od 100); manje često (javljaju se kod 1 do 10 korisnika od 1000); rijetko (javljaju se kod 1 do 10 korisnika od 10 000); vrlo rijetko (javljaju se kod 1 od 10 000 korisnika); nepoznato (učestalost se ne može utvrditi na temelju dostupnih podataka).
English: Common: urinary incontinence Common: urinary incontinence
Croatian: Često: inkontinencija urina
English: Systemic exposure to cytarabine was determined to be negligible following intrathecal administration of 50 mg and 75 mg of DepoCyte.
Croatian: Sistemska izloženost citarabinu nakon intratekalne primjene doza od 50 mg i 75 mg DepoCytea pokazala se kao zanemariva.
English: Precautions for the handling and disposal of DepoCyte
Croatian: Mjere opreza kod rukovanja i zbrinjavanja DepoCytea
English: • A stiff or rigid neck
Croatian: • Zakočen ili ukočen vrat
English: Blockage or reduction of CSF flow may result in increased free cytarabine concentrations in the CSF with increased risk of neurotoxicity.
Croatian: Prekid ili smanjenje protoka cerebrospinalne tekućine može imati za posljedicu povišenu koncentraciju slobodnog citarabina u cerebrospinalnoj tekućini uz povišen rizik neurotoksičnosti.
English: Cytarabine is a cell-cycle phase specific antineoplastic agent, affecting cells only during the S-phase of cell division.
Croatian: Citarabin je antineoplastički agens koji djeluje na specifičnu fazu staničnog ciklusa, tj. djeluje samo na stanice koje se nalaze u S-fazi stanične diobe.
English: Adverse reactions occurring in > 10% of cycles in either treatment group in Phase 1-4 study patients with lymphomatous meningitis receiving DepoCyte 50 mg (n = 151 cycles) or cytarabine (n = 99 cycles)
Croatian: Nuspojave koje se pojavljuju u > 10% ciklusa liječenja, u fazama 1-4 kliničkog ispitivanja, u pacijenata s limfomatoznim meningitisom koji su primali ili DepoCyte 50 mg (n = 151 ciklus) ili citarabin (n = 99 ciklusa)
English: Very Common: weakness Common: pain Very Common: weakness Common: pain
Croatian: Vrlo često: opća slabost Često: bol
English: Each vial contains 50 mg cytarabine (10 mg/ml).
Croatian: TVARI Jedna bočica sadrži 50 mg citarabina (10 mg/ml).
English: Exchange of cerebrospinal fluid with isotonic sodium chloride solution has been carried out in a case of intrathecal overdose of free cytarabine and such a procedure may be considered in the case of DepoCyte overdose.
Croatian: U jednom slučaju intratekalnog predoziranja slobodnim citarabinom provedena je izmjena cerebrospinalne tekućine izotoničnom otopinom natrijeva klorida, te se takav postupak može razmotriti u slučaju predoziranja DepoCytea.
English: • Infection of the meninges
Croatian: • Infekcija meningealnih ovojnica
English: Almac Pharma Services Limited, 20 Seagoe Industrial Estate, Craigavon, Co Armagh, BT63 5QD, United Kingdom.
Croatian: Almac Pharma Services Limited, 20 Seagoe Industrial Estate, Craigavon, Co Armagh, BT63 5QD, Ujedinjeno Kraljevstvo.
English: Do not use this medicine after the expiry date which is stated on the carton and on the vial after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji ili bočici iza oznake Rok valjanosti ili EXP.
English: Preparation of DepoCyte Given its toxic nature, special precautions should be taken in handling DepoCyte.
Croatian: Zbog toksičnosti potrebne su posebne mjere opreza pri rukovanju DepoCyteom.
English: Cytarabine (n = 99 cycles)
Croatian: Citarabin (n = 99 ciklusa)
English: Hydrocephalus has also been reported, possibly precipitated by arachnoiditis.
Croatian: Opisani su slučajevi hidrocefalusa, vjerojatno povezani s arahnoiditisom.